CN1840052A - Preparation method of notoginseng-containing tablet for treating traumatic injury - Google Patents
Preparation method of notoginseng-containing tablet for treating traumatic injury Download PDFInfo
- Publication number
- CN1840052A CN1840052A CNA2006100018231A CN200610001823A CN1840052A CN 1840052 A CN1840052 A CN 1840052A CN A2006100018231 A CNA2006100018231 A CN A2006100018231A CN 200610001823 A CN200610001823 A CN 200610001823A CN 1840052 A CN1840052 A CN 1840052A
- Authority
- CN
- China
- Prior art keywords
- weight portion
- notoginseng
- traumatic injury
- cinnabaris
- preparation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Landscapes
- Medicines Containing Plant Substances (AREA)
- Medicinal Preparation (AREA)
Abstract
The invention relates to a preparation method of notoginseng-containing tablet for treating traumatic injury, which comprises comminuting cinnabar, musk, dragon's blood resin, baras camphor, notoginseng, myrrh, safflower, frankincense, Chinese angelica root and black catechu, mixing and sieving to obtain granules, drying and charging musk, baras camphor fines, mixing homogenously and tabletting.
Description
Technical field
The present invention relates to the processing technology technical field of Chinese patent medicine tablet, the preparation method of the notoginseng-containing tablet for treating traumatic injury of the treatment traumatic injury of more specifically saying so.
Background technology
Tablet, powder all are pharmaceutical formulations that pharmacopeia write down, and tablet is a kind of pharmaceutical formulation particularly commonly used.Original dosage form of prior art is: the Flos Carthami Anisodus carniolicoides C.Y.Wu et C.Chen, listed in country of the national Bureau of Drugs Supervision standard for traditional Chinese medicines compilation.Though the powder onset is rapid, but take inconvenience, divided dose is inaccurate, can not satisfy people's medication demand, prior art is improved the pharmaceutical formulation aspect, but owing to raw material powder must be broken into fine powder, and, production cost and process time have been ignored in the prior art in order to reach high usage.
The Chinese patent literature patent No. be 03118286.0 (publication number CN1537580A) the publication reported in literature Flos Carthami notoginseng-containing tablet and preparation method.Its prescription be with 10-40g Cinnabaris, 0.2-1.0g Moschus, 1-3g Borneolum Syntheticum, 10-40g Olibanum, 10-40g Flos Carthami, 30-110g Sanguis Draxonis, 1-6g Radix Angelicae Sinensis, 18-65g catechu, 60-210g Lignum Dalbergiae Odoriferae, 60-210g Radix Notoginseng, 10-40 Myrrha ten simply medical material be raw material and an amount of adjuvant.
This preparation method be with ten simply medical material be raw material, Cinnabaris is ground into impalpable powder; Moschus, Borneolum Syntheticum are ground into fine powder respectively; All the other Olibanums, Flos Carthami, Sanguis Draxonis, Radix Angelicae Sinensis, catechu, Lignum Dalbergiae Odoriferae, Radix Notoginseng, Myrrha eight flavors are ground into fine powder, with above-mentioned Cinnabar mixing, granulate, and drying adds Moschus, Borneolum Syntheticum fine powder and right amount of auxiliary materials, and mixing, tabletting makes the Flos Carthami notoginseng-containing tablet.
Pulverizing medicinal materials in its technology becomes fine powder to be generally the 80-160 order, is preferably superfine powder and is broken into 200-300 purpose fine powder.
The prepared Flos Carthami notoginseng-containing tablet that comes out of this patented method, it is evident in efficacy, carries, easy to use, too high but its weak point is the fine powder order number that preparation method was ground into of prior art, technological process is longer, has increased medical materials such as Lignum Dalbergiae Odoriferae again and has made cost too high.
Summary of the invention
Purpose of the present invention just is to work out a kind of new method for preparing notoginseng-containing tablet for treating traumatic injury, overcomes the shortcoming that manufacturing procedure is loaded down with trivial details in the prior art, cost of manufacture is high.
In order to reach goal of the invention, researcher of the present invention can reach ideal effect and can simplify and carry out many research work on the production technology raw material powder being broken into how many orders.Usually, high more through the order number of micronizing, availability is just high more, but experimental result shows, is enough to reach ideal effect with the products material utilization rate of this preparation method gained, and production technology has been simplified a lot, has saved resource.Comprehensive above-mentioned drug effect, production cost and time, many-sided factor considered that the inventor has worked out the preparation method of notoginseng-containing tablet for treating traumatic injury, the notoginseng-containing tablet for treating traumatic injury utilization rate height of preparing in this way, and production technology is simple, and is with low cost.
The preparation method of a kind of notoginseng-containing tablet for treating traumatic injury of the present invention, its proportioning raw materials are 40-50 weight portion Cinnabaris, 0.5-1.0 weight portion Moschus, 10-25 weight portion Sanguis Draxonis, 1-1.6 weight portion Borneolum Syntheticum, 5-50 weight portion Radix Notoginseng, 20-40 weight portion Myrrha, 41-60 weight portion Flos Carthami, 20-40 weight portion Olibanum, 60-100 weight portion Radix Angelicae Sinensis, 30-50 weight portion catechu;
Its preparation method is standby for Cinnabaris is ground into 120 orders-200 purpose impalpable powder, is good to be ground into 120 orders-180 order again; Respectively Moschus, Sanguis Draxonis, Borneolum Syntheticum are ground into 60 orders-80 purpose fine powder respectively; All the other Radix Notoginseng, Myrrha, Flos Carthami, Olibanum, Radix Angelicae Sinensis, catechu Six-element medical material pulverize separately become 60 orders-80 purpose fine powder, with Radix Notoginseng, Myrrha, Flos Carthami, Olibanum, Radix Angelicae Sinensis, catechu fine powder and above-mentioned Cinnabaris impalpable powder, fine powder of dragons blood mixing, sieve, make granule, drying adds Moschus, Borneolum Syntheticum fine powder and adjuvant, mixing again, tabletting makes notoginseng-containing tablet for treating traumatic injury.
Used adjuvant is in the technology: wherein at least a of Pulvis Talci, microcrystalline Cellulose, polyvinylpolypyrrolidone, carboxymethylstach sodium, 30 POVIDONE K 30 BP/USP 30, micropowder silica gel, low-substituted hydroxypropyl cellulose, starch, dextrin, magnesium stearate, consumption is good to add 9 weight portion adjuvants again at the 5-15 weight portion.
Its best proportioning is 40.1-50 weight portion Cinnabaris, 0.5-1.0 weight portion Moschus, 16.5-25 weight portion Sanguis Draxonis, 1-1.55 weight portion Borneolum Syntheticum, 8.1-45 weight portion Radix Notoginseng, 25-31.9 weight portion Myrrha, 41-47.5 weight portion Flos Carthami, 20-31.5 weight portion Olibanum, 60-79.9 weight portion Radix Angelicae Sinensis, 30-39.9 weight portion catechu.
Described weight portion can be weight metering units such as gram, two, jin, kilogram, ton.
Ten used flavor medical materials are the Chinese crude drug that commercially available process is up to the standards.
The granule of making after sieving, can adopt spray drying method when carrying out drying is the 5%-9% percetage by weight with particle drying to moisture in spray-drying pelleting machine (PGL-80 type, wide summer of Chongqing drying equipment engineering company produce).Wherein the inlet temperature in the dry run is controlled at 70 ℃-90 ℃, and temperature of charge is controlled at 40 ℃-55 ℃, is 80 ℃ with inlet temperature again, and it is good that temperature of charge is 50 ℃, is 7% with particle drying to moisture preferably, in order to avoid prepared tablet is easily dry and cracked.
The granule of making after sieving, also can adopt heated-air circulation oven (CT-C-II type when carrying out drying, Changxing, Nanjing pharmaceutical machine company limited is produced) directly dry to moisture be the 5%-9% percetage by weight, temperature is controlled at 45 ℃-60 ℃, with moisture is 7%, and it is good that temperature is 50 ℃.
Cinnabaris is ground into impalpable powder and adopts elutriation in the described preparation method.It is that thick Cinnabaris is suitably broken that Cinnabaris water flies, and puts in the mortar or in other containers, adds proper amount of clear water, grinds to form pasty state, adds water gaging again and stirs, and coarse grain promptly sinks, and inclines immediately to suspension, and the coarse grain of sinking grinds again, and repeatable operation like this is till porphyrize.Impurity that at last can not suspendible discards.The suspension merging that anteversion and retroversion go out is left standstill, treat post precipitation, the top clear water that inclines grinds to form superfine powder with dry sediment.
The notoginseng-containing tablet for treating traumatic injury for preparing with method of the present invention have invigorate blood circulation, dissipating blood stasis, detumescence, analgesic effect, be used for traumatic injury, traumatic hemorrhage.The detailed directions consumption is oral, a 1-3 sheet, 3 times on the one, also available (medicine) to be taken with wine.
In order further to estimate the curative effect and the safety of this medicine clinical application, medicine of the present invention is in strict accordance with the clinical research scheme, adopt with the FUFANG SANQI JIAONANG be the contrast medicine at random, test method parallel, positive control carries out clinical research to it.From in January, 2004 to 2004 year JIUYUE, through 9 months clinical verification, observe complete case 100 examples altogether, test group 72 examples wherein, matched group 28 examples.Now result of study is reported in down:
(1) experimenter goes into the group situation
Group 103 examples are gone in test, and the case that comes off is 3 examples, and expulsion rate is 2.91%, collect complete case 100 examples that meet scheme altogether, test group 72 examples wherein, matched group 28 examples.
(2) two groups of analysis of comparable
1, two groups of patient's sex ratios see Table 1
Table 1 liang group patient sex composition relatively
| Group | The example number | The man | ％ | The woman | ％ | x 2 | p |
| Treatment group matched group | 72 28 | 39 14 | 54.17 50 | 33 14 | 43.85 50 | 0.1405 | 0.7072 |
Two groups of patient's sex ratios, through x
2Check, by proofreading and correct probability or definite probability P＞0.05 (P=0.7072), difference does not have significance.
2, two groups of patient ages distribute and relatively see Table 2
Table 2 a liang group patient age distributes relatively
| Group | The example number | 16～ | 30～ | 40～ | 50～ | 60～ | U | P |
| Treatment group matched group | 72 28 | 23 9 | 17 8 | 16 6 | 9 3 | 7 2 | 0.3549 | 0.7221 |
Analyze there was no significant difference in group age distribution of P＞0.05, two through Ridit.
3, two groups of patients clinic case distribution situation of being in hospital sees Table 3
Table 3 is the clinic case distribution situation in hospital
| Group | The example number | Be in hospital | Outpatient service | x 2 |
| Treatment group matched group | 72 28 | 21 8 | 51 20 | 0.0035 |
Through x
2Statistics, P＞0.05 (P=0.9529), two groups be in hospital, clinic case distributes and goes up there was no significant difference.
4, two groups of conditions of patients relatively see Table 4
The table 4 liang group state of an illness relatively
| Group | The example number | Slightly | Moderate | Severe | U | P |
| Treatment group matched group | 72 28 | 27 11 | 26 10 | 19 7 | 0.1679 | 0.8649 |
Analyze through Ridit, P＞0.05, the two group state of an illness distributes and goes up there was no significant difference.
5, two groups of courses of disease distribute relatively
Table 5 a liang group course of disease distributes relatively
| Group | The example number | Course of disease distribution (my god) | ||
| ＜1 | 1～2 | 3～ | ||
| Treatment group matched group | 72 28 | 37 14 | 23 9 | 12 5 |
The course of disease distributes relatively between group, learns by statistics and handles P＞0.05, (U=0.1350 P=0.8923) there was no significant difference.
6, two groups of preceding tcm symptom size scales of patient treatment see Table 6
The tcm symptom size scale before table 6 treatment
| Cardinal symptom | Classification | Test group | Matched group | U | P | ||
| n | ％ | n | ％ | ||||
| Pain | There is not slight moderate severe | 0 34 30 8 | 0.00 47.22 41.67 11.11 | 0 14 11 3 | 0.00 50 39.29 10.71 | 0.2083 | 0.8346 |
| Tenderness | There is not slight moderate severe | 0 33 28 11 | 0.00 45.83 38.89 15.28 | 0 15 13 3 | 0.00 53.57 46.23 10.71 | 0.4190 | 0.6746 |
| Swelling | There is not slight moderate severe | 22 27 14 9 | 30.56 37.5 19.44 12.5 | 5 11 8 4 | 17.86 39.29 28.57 14.29 | 1.1997 | 0.2297 |
| Dysfunction | There is not slight moderate severe | 17 31 19 5 | 23.61 43.06 26.39 6.94 | 5 12 8 3 | 17.86 42.86 28.57 10.71 | 0.7175 | 0.4723 |
| Ecchymosis | There is not slight moderate severe | 15 24 20 13 | 20.83 33.33 20.78 18.06 | 4 9 8 7 | 14.29 32.14 28.57 25 | 0.8911 | 0.3722 |
The result shows, before two groups of patient treatments the tcm symptom size scales, there was no significant difference.
Statistical result shows, treatment group, the sex of matched group case, age distribution, and difference that aspects such as cardinal symptom add up after testing that there are no significant shows that two groups of cases are evenly distributed, and have comparability.
(3) curative effect relatively
1, general curative effect relatively sees Table 7
The comparison of table 7 liang group general curative effect
| Group | The example number | Recovery from illness | Produce effects | Effectively | Invalid | Cure-remarkable-effectiveness rate (%) | Total effective rate (%) |
| Treatment group matched group | 72 28 | 20 7 | 23 9 | 24 9 | 5 3 | 59.72 57.14 | 93.06 89.29 |
Analyze through Ridit, U=0.3780, P＞0.05 (P=0.7048), two groups of general curative effects compare there was no significant difference.
2, the cardinal symptom curative effect compares (seeing Table 8,9,10,11)
Table 8 liang group is to the comparison of pain curative effect
| Group | The example number | Recovery from illness | Produce effects | Effectively | Invalid | Cure-remarkable-effectiveness rate (%) | Effective percentage (%) |
| Treatment group matched group | 72 28 | 23 8 | 22 8 | 21 8 | 6 4 | 62.5 57.14 | 91.67 85.71 |
Analyze U=0.5864, P＞0.05 (P=0.5569), two groups of comparison there was no significant differences to the arthralgia curative effect through Ridit.
Table 9 liang group is to the comparison of tenderness curative effect
| Group | The example number | Recovery from illness | Produce effects | Effectively | Invalid | Cure-remarkable-effectiveness rate (%) | Effective percentage (%) |
| Treatment group matched group | 72 28 | 25 9 | 23 8 | 22 9 | 2 2 | 66.67 60.71 | 97.22 92.86 |
Analyze U=0.5362, P＞0.05 (P=0.5911), two groups of comparison there was no significant differences to the tenderness curative effect through Ridit.
Table 10 liang group is to the comparison of swelling curative effect
| Group | The example number | Recovery from illness | Produce effects | Effectively | Invalid | Cure-remarkable-effectiveness rate (%) | Effective percentage (%) |
| Treatment group matched group | 50 23 | 13 6 | 17 7 | 15 7 | 5 3 | 60 56.52 | 90 86.96 |
Analyze U=0.2331, P＞0.05 (P=0.8152), two groups of comparison there was no significant differences to the arthroncus curative effect through Ridit.
Table 11 liang group is to the comparison of ecchymosis curative effect
| Group | The example number | Recovery from illness | Produce effects | Effectively | Invalid | Cure-remarkable-effectiveness rate (%) | Effective percentage (%) |
| Treatment group matched group | 57 24 | 13 5 | 16 6 | 19 8 | 9 5 | 50.88 45.83 | 84.21 79.17 |
Analyze U=0.4683, P＞0.05 (P=0.6389), two groups of comparison there was no significant differences to the ecchymosis curative effect through Ridit.
Four, model case
The patient poplar, woman, 23 years old.On August 5th, 2004 went to a doctor.Traumatic injury by bike before 3 hours, right sprain of ankle.Right ankle swelling is obvious, local livid purple ecchymosis 6cm * 7cm, pain very, difficulty in walking.Take the photograph sheet through X and do not see fracture.Diagnosis: acute articular sprain.Chinese medical discrimination: syndrome of qi stagnation and blood stasis.Darling renal function detects normal; Give each 3 of notoginseng-containing tablet for treating traumatic injury, every day 3 times, Chinese liquor takes.The 1 day local pain of taking medicine obviously alleviates, and local congestive edema begins to disappear after 4 days, and take medicine 7 days local swellings, pain, ecchymosis disappear substantially, can be engaged in normal activity, check, and darling renal function is normal.
The excellent results of the preparation method of notoginseng-containing tablet for treating traumatic injury of the present invention is:
(1) it is suitable that the notoginseng-containing tablet for treating traumatic injury for preparing with method of the present invention makes the fine powder order number of raw material pulverizing, makes medicine be easy to absorb and reduced processing step.
(2) method technology of the present invention is brief, energy-conservation, has reduced the cost of product.
(3) notoginseng-containing tablet for treating traumatic injury for preparing with method of the present invention is evident in efficacy, carries, easy to use.Oral result is obvious.
The specific embodiment
Below with embodiment method of the present invention is described further, help further understanding to notoginseng-containing tablet for treating traumatic injury preparation method of the present invention, embodiment does not limit protection scope of the present invention, its protection domain is decided by claim.
Embodiment 1
With 40.1g Cinnabaris, 0.75g Moschus, 20g Sanguis Draxonis, 1.5g Borneolum Syntheticum, 10g Radix Notoginseng, 30g Myrrha, 50g Flos Carthami, 40g Olibanum, 85g Radix Angelicae Sinensis, 42.5g catechu ten flavor medical materials is raw material; It is standby to adopt elutriation that Cinnabaris is ground into 120 purpose impalpable powders; respectively with Moschus; Sanguis Draxonis; Borneolum Syntheticum is ground into 80 purpose fine powders; all the other Radix Notoginseng; Myrrha; Flos Carthami; Olibanum; Radix Angelicae Sinensis; catechu Six-element medical material pulverize separately becomes 80 purpose fine powders; with Radix Notoginseng; Myrrha; Flos Carthami; Olibanum; Radix Angelicae Sinensis; catechu fine powder and above-mentioned Cinnabaris impalpable powder; the fine powder of dragons blood mixing; with Moschus; Sanguis Draxonis; Borneolum Syntheticum; Radix Notoginseng; Myrrha; Flos Carthami; Olibanum; Radix Angelicae Sinensis; catechu is ground into fine powder and all uses commercially available dust-free pulverizing mill (TF-450B or TF-350B type; Harbin nano pharmacy complete set of equipments company limited is produced); sieve then; make granule; in 90 ℃ of inlet temperature; under the temperature that temperature of charge is 40 ℃ with commercially available spray-drying pelleting machine (PGL-80 type; drying equipment engineering company product of wide summer of Chongqing) carrying out spray drying to moisture is 5% (percetage by weight); add Moschus; Borneolum Syntheticum fine powder and adjuvant Pulvis Talci; microcrystalline Cellulose; polyvinylpolypyrrolidone; carboxymethylstach sodium; 30 POVIDONE K 30 BP/USP 30 is any one or any five kinds of adjuvants of weight ratio wherein wherein; consumption is 9g; mixing; tabletting is made notoginseng-containing tablet for treating traumatic injury.
Embodiment 2
Its device therefor and operational approach thereof are substantially with embodiment 1, have only and different be, with 41g Cinnabaris, 0.5g Moschus, the 15g Sanguis Draxonis, 1.35g Borneolum Syntheticum, the 35g Radix Notoginseng, the 25g Myrrha, the 53g Flos Carthami, 27.5g Olibanum, the 65g Radix Angelicae Sinensis, 40g catechu ten flavor medical materials are raw material, it is standby to adopt elutriation that Cinnabaris is ground into 120 purpose impalpable powders, respectively with Moschus, Sanguis Draxonis, Borneolum Syntheticum is ground into 70 purpose fine powders, all the other Radix Notoginseng, Myrrha, Flos Carthami, Olibanum, Radix Angelicae Sinensis, catechu Six-element medical material pulverize separately becomes 70 purpose fine powders, in 90 ℃ of inlet temperature, carrying out spray drying to moisture under the temperature that temperature of charge is 45 ℃ is 6% (percetage by weight), add the adjuvant micropowder silica gel, low-substituted hydroxypropyl cellulose, starch, dextrin, magnesium stearate is any one or any four kinds of adjuvants of weight ratio wherein wherein, and consumption is 5g.
Embodiment 3
Its device therefor and operational approach thereof are substantially with embodiment 1, have only and different be, with 45g Cinnabaris, 0.9g Moschus, the 23g Sanguis Draxonis, 1.25g Borneolum Syntheticum, the 20g Radix Notoginseng, the 20g Myrrha, the 41g Flos Carthami, the 30g Olibanum, the 90g Radix Angelicae Sinensis, 50g catechu ten flavor medical materials are raw material, it is standby to adopt elutriation that Cinnabaris is ground into 140 purpose impalpable powders, respectively with Moschus, Sanguis Draxonis, Borneolum Syntheticum is ground into 80 purpose fine powders, all the other Radix Notoginseng, Myrrha, Flos Carthami, Olibanum, Radix Angelicae Sinensis, catechu Six-element medical material pulverize separately becomes 80 purpose fine powders, in 85 ℃ of inlet temperature, carrying out spray drying to moisture under the temperature that temperature of charge is 40 ℃ is 6% (percetage by weight), add microcrystalline cellulose excipients, carboxymethylstach sodium, micropowder silica gel, starch, magnesium stearate is any one or any three kinds of adjuvants of weight ratio wherein wherein, and consumption is 10g.
Embodiment 4
Its device therefor and operational approach thereof are substantially with embodiment 1, have only and different be, with 43g Cinnabaris, 1.0g Moschus, the 10g Sanguis Draxonis, the 1g Borneolum Syntheticum, the 15g Radix Notoginseng, the 40g Myrrha, the 60g Flos Carthami, 31.5g Olibanum, the 80g Radix Angelicae Sinensis, 37.5g catechu ten flavor medical materials are raw material, it is standby to adopt elutriation that Cinnabaris is ground into 140 purpose impalpable powders, respectively with Moschus, Sanguis Draxonis, Borneolum Syntheticum is ground into 70 purpose fine powders, all the other Radix Notoginseng, Myrrha, Flos Carthami, Olibanum, Radix Angelicae Sinensis, catechu Six-element medical material pulverize separately becomes 70 purpose fine powders, in 85 ℃ of inlet temperature, carrying out spray drying to moisture under the temperature that temperature of charge is 45 ℃ is 7% (percetage by weight), add the adjuvant Pulvis Talci, polyvinylpolypyrrolidone, 30 POVIDONE K 30 BP/USP 30, low-substituted hydroxypropyl cellulose, dextrin is any one or wherein any two kinds of adjuvants wherein, and consumption is 15g.
Embodiment 5
Its device therefor and operational approach thereof are substantially with embodiment 1, have only and different be, with 50g Cinnabaris, 0.85g Moschus, 16.5g Sanguis Draxonis, 1.55g Borneolum Syntheticum, the 50g Radix Notoginseng, 31.9g Myrrha, 47.5g Flos Carthami, 31.5g Olibanum, the 100g Radix Angelicae Sinensis, 39.9g catechu ten flavor medical materials are raw material, it is standby to adopt elutriation that Cinnabaris is ground into 150 purpose impalpable powders, respectively with Moschus, Sanguis Draxonis, Borneolum Syntheticum is ground into 70 purpose fine powders, all the other Radix Notoginseng, Myrrha, Flos Carthami, Olibanum, Radix Angelicae Sinensis, catechu Six-element medical material pulverize separately becomes 70 purpose fine powders, in 80 ℃ of inlet temperature, carrying out spray drying to moisture under the temperature that temperature of charge is 45 ℃ is 7% (percetage by weight), add microcrystalline cellulose excipients, polyvinylpolypyrrolidone, starch, dextrin, magnesium stearate is any one or any two kinds of adjuvants of weight ratio wherein wherein, and consumption is 11g.
Embodiment 6
Its device therefor and operational approach thereof are substantially with embodiment 1, have only and different be, with 45g Cinnabaris, 0.85g Moschus, 17.5g Sanguis Draxonis, 1.45g Borneolum Syntheticum, the 25g Radix Notoginseng, 32.1g Myrrha, 47.5g Flos Carthami, 37.5g Olibanum, the 75g Radix Angelicae Sinensis, 30g catechu ten flavor medical materials are raw material, it is standby to adopt elutriation that Cinnabaris is ground into 150 purpose impalpable powders, respectively with Moschus, Sanguis Draxonis, Borneolum Syntheticum is ground into 65 purpose fine powders, all the other Radix Notoginseng, Myrrha, Flos Carthami, Olibanum, Radix Angelicae Sinensis, catechu Six-element medical material pulverize separately becomes 65 purpose fine powders, in 80 ℃ of inlet temperature, carrying out spray drying to moisture under the temperature that temperature of charge is 50 ℃ is 9% (percetage by weight), add the adjuvant carboxymethylstach sodium, 30 POVIDONE K 30 BP/USP 30, starch, dextrin, magnesium stearate wherein any one, consumption is 12g.
Embodiment 7
Its device therefor and operational approach thereof are substantially with embodiment 1, have only and different be, with 46g Cinnabaris, 0.6g Moschus, the 10g Sanguis Draxonis, 1.4g Borneolum Syntheticum, the 40g Radix Notoginseng, the 40g Myrrha, the 48g Flos Carthami, the 20g Olibanum, the 100g Radix Angelicae Sinensis, 47.5g catechu ten flavor medical materials are raw material, it is standby to adopt elutriation that Cinnabaris is ground into 180 purpose impalpable powders, respectively with Moschus, Sanguis Draxonis, Borneolum Syntheticum is ground into 70 purpose fine powders, all the other Radix Notoginseng, Myrrha, Flos Carthami, Olibanum, Radix Angelicae Sinensis, catechu Six-element medical material pulverize separately becomes 70 purpose fine powders, in 75 ℃ of inlet temperature, carrying out spray drying to moisture under the temperature that temperature of charge is 50 ℃ is 8% (percetage by weight), add microcrystalline cellulose excipients, polyvinylpolypyrrolidone, micropowder silica gel, low-substituted hydroxypropyl cellulose, magnesium stearate wherein any one, consumption is 13g.
Embodiment 8
Its device therefor and operational approach thereof are substantially with embodiment 1, have only and different be, with 47g Cinnabaris, 0.95g Moschus, the 25g Sanguis Draxonis, 1.2g Borneolum Syntheticum, the 5g Radix Notoginseng, 22.5g Myrrha, the 45g Flos Carthami, the 23g Olibanum, the 95g Radix Angelicae Sinensis, 30g catechu ten flavor medical materials are raw material, it is standby to adopt elutriation that Cinnabaris is ground into 180 purpose impalpable powders, respectively with Moschus, Sanguis Draxonis, Borneolum Syntheticum is ground into 65 purpose fine powders, all the other Radix Notoginseng, Myrrha, Flos Carthami, Olibanum, Radix Angelicae Sinensis, catechu Six-element medical material pulverize separately becomes 65 purpose fine powders, in 75 ℃ of inlet temperature, carrying out spray drying to moisture under the temperature that temperature of charge is 55 ℃ is 8% (percetage by weight), add the adjuvant carboxymethylstach sodium, 30 POVIDONE K 30 BP/USP 30, micropowder silica gel, low-substituted hydroxypropyl cellulose, magnesium stearate wherein any one, consumption is 14g.
Embodiment 9
Its device therefor and operational approach thereof are substantially with embodiment 1, have only and different be, with 48g Cinnabaris, 0.55g Moschus, the 13g Sanguis Draxonis, 1.3g Borneolum Syntheticum, the 30g Radix Notoginseng, 27.5g Myrrha, 57.5g Flos Carthami, the 20g Olibanum, the 60g Radix Angelicae Sinensis, 33g catechu ten flavor medical materials are raw material, it is standby to adopt elutriation that Cinnabaris is ground into 180 purpose impalpable powders, respectively with Moschus, Sanguis Draxonis, Borneolum Syntheticum is ground into 60 purpose fine powders, all the other Radix Notoginseng, Myrrha, Flos Carthami, Olibanum, Radix Angelicae Sinensis, catechu Six-element medical material pulverize separately becomes 60 purpose fine powders, under 45 ℃ temperature, dry to moisture be 5% (percetage by weight), add the adjuvant Pulvis Talci, microcrystalline Cellulose, carboxymethylstach sodium, low-substituted hydroxypropyl cellulose, dextrin wherein any one, consumption is 6g.
Embodiment 10
Its device therefor and operational approach thereof are substantially with embodiment 1, have only and different be, with 49g Cinnabaris, 0.8g Moschus, 16.5g Sanguis Draxonis, 1.55g Borneolum Syntheticum, the 45g Radix Notoginseng, 33.5g Myrrha, the 47g Flos Carthami, 21.5g Olibanum, the 82g Radix Angelicae Sinensis, 39g catechu ten flavor medical materials are raw material, it is standby to adopt elutriation that Cinnabaris is ground into 200 purpose impalpable powders, respectively with Moschus, Sanguis Draxonis, Borneolum Syntheticum is ground into 65 purpose fine powders, all the other Radix Notoginseng, Myrrha, Flos Carthami, Olibanum, Radix Angelicae Sinensis, catechu Six-element medical material pulverize separately becomes 65 purpose fine powders, under 50 ℃ temperature, dry to moisture be 6% (percetage by weight), add the adjuvant Pulvis Talci, polyvinylpolypyrrolidone, 30 POVIDONE K 30 BP/USP 30, starch, magnesium stearate wherein any one, consumption is 7g.
Embodiment 11
Its device therefor and operational approach thereof are substantially with embodiment 1, have only and different be, with 50g Cinnabaris, 0.65g Moschus, 21.5g Sanguis Draxonis, 1.6g Borneolum Syntheticum, the 8g Radix Notoginseng, the 21g Myrrha, 51.5g Flos Carthami, 38.5g Olibanum, 62.5g Radix Angelicae Sinensis, 41.5g catechu ten flavor medical materials are raw material, it is standby to adopt elutriation that Cinnabaris is ground into 200 purpose impalpable powders, respectively with Moschus, Sanguis Draxonis, Borneolum Syntheticum is ground into 60 purpose fine powders, all the other Radix Notoginseng, Myrrha, Flos Carthami, Olibanum, Radix Angelicae Sinensis, catechu Six-element medical material pulverize separately becomes 60 purpose fine powders, under 55 ℃ temperature in commercially available heated-air circulation oven (CT-C-II type, Changxing, Nanjing pharmaceutical machine company limited is produced) dry to moisture be 7% (percetage by weight), add the adjuvant Pulvis Talci, polyvinylpolypyrrolidone, carboxymethylstach sodium, low-substituted hydroxypropyl cellulose, dextrin, magnesium stearate wherein any one, consumption is 8g.
Embodiment 12
Its device therefor and operational approach thereof are substantially with embodiment 1, have only and different be, with 40g Cinnabaris, 0.7g Moschus, 21.5g Sanguis Draxonis, 1.1g Borneolum Syntheticum, 8.1g Radix Notoginseng, the 37g Myrrha, the 41g Flos Carthami, the 34g Olibanum, 79.9g Radix Angelicae Sinensis, 45g catechu ten flavor medical materials are raw material, it is standby to adopt elutriation that Cinnabaris is ground into 200 purpose impalpable powders, respectively with Moschus, Sanguis Draxonis, Borneolum Syntheticum is ground into 70 purpose fine powders, all the other Radix Notoginseng, Myrrha, Flos Carthami, Olibanum, Radix Angelicae Sinensis, catechu Six-element medical material pulverize separately becomes 70 purpose fine powders, under 60 ℃ temperature, dry to moisture be 8% (percetage by weight), add the adjuvant Pulvis Talci, polyvinylpolypyrrolidone, carboxymethylstach sodium, low-substituted hydroxypropyl cellulose, dextrin, magnesium stearate wherein any one, consumption is 9g.
Embodiment 13
Its device therefor and operational approach thereof be substantially with embodiment 12, has only different to be, under 60 ℃ temperature, dry to moisture be 9% (percetage by weight).
Claims (7)
1, a kind of preparation method of notoginseng-containing tablet for treating traumatic injury is characterized in that,
1) its proportioning raw materials is 40-50 weight portion Cinnabaris, 0.5-1.0 weight portion Moschus, 10-25 weight portion Sanguis Draxonis, 1-1.6 weight portion Borneolum Syntheticum, 5-50 weight portion Radix Notoginseng, 20-40 weight portion Myrrha, 41-60 weight portion Flos Carthami, 20-40 weight portion Olibanum, 60-100 weight portion Radix Angelicae Sinensis, 30-50 weight portion catechu;
2) it is standby Cinnabaris to be ground into 120 orders-200 purpose impalpable powder; Respectively Moschus, Sanguis Draxonis, Borneolum Syntheticum are ground into 60 orders-80 purpose fine powder respectively; All the other Radix Notoginseng, Myrrha, Flos Carthami, Olibanum, Radix Angelicae Sinensis, catechu Six-element medical material pulverize separately become 60 orders-80 purpose fine powder, with Radix Notoginseng, Myrrha, Flos Carthami, Olibanum, Radix Angelicae Sinensis, catechu fine powder and above-mentioned Cinnabaris impalpable powder, fine powder of dragons blood mixing, sieve, make granule, drying adds Moschus, Borneolum Syntheticum fine powder and adjuvant, mixing again, tabletting makes notoginseng-containing tablet for treating traumatic injury.
2, the preparation method of a kind of notoginseng-containing tablet for treating traumatic injury according to claim 1, it is characterized in that proportioning raw materials is 40.1-50 weight portion Cinnabaris, 0.5-1.0 weight portion Moschus, 16.5-25 weight portion Sanguis Draxonis, 1-1.55 weight portion Borneolum Syntheticum, 8.1-45 weight portion Radix Notoginseng, 25-31.9 weight portion Myrrha, 41-47.5 weight portion Flos Carthami, 20-31.5 weight portion Olibanum, 60-79.9 weight portion Radix Angelicae Sinensis, 30-39.9 weight portion catechu.
3, the preparation method of a kind of notoginseng-containing tablet for treating traumatic injury according to claim 1, it is characterized in that, used adjuvant is: wherein at least a of Pulvis Talci, microcrystalline Cellulose, polyvinylpolypyrrolidone, carboxymethylstach sodium, 30 POVIDONE K 30 BP/USP 30, micropowder silica gel, low-substituted hydroxypropyl cellulose, starch, dextrin, magnesium stearate, consumption is at the 5-15 weight portion.
4, according to the preparation method of claim 1,2 a kind of notoginseng-containing tablet for treating traumatic injury wherein, it is characterized in that, the granule of making after sieving, can adopt spray drying method when carrying out drying is the 5%-9% percetage by weight with particle drying to moisture, inlet temperature is controlled at 70 ℃-90 ℃, and temperature of charge is controlled at 40 ℃-55 ℃.
5, according to the preparation method of claim 1,2 a kind of notoginseng-containing tablet for treating traumatic injury wherein, it is characterized in that, the granule of making after sieving, can adopt oven drying method when carrying out drying is the 5%-9% percetage by weight with particle drying to moisture, temperature is controlled at 45 ℃-60 ℃.
6, according to the preparation method of claim 1,3 a kind of notoginseng-containing tablet for treating traumatic injury wherein, it is characterized in that, Cinnabaris is ground into impalpable powder adopts elutriation.
7, the preparation method of a kind of notoginseng-containing tablet for treating traumatic injury according to claim 1 is characterized in that, it is standby that Cinnabaris is ground into 120 orders-180 purpose impalpable powder.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB2006100018231A CN100387277C (en) | 2006-01-23 | 2006-01-23 | Preparation method of notoginseng-containing tablet for treating traumatic injury |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB2006100018231A CN100387277C (en) | 2006-01-23 | 2006-01-23 | Preparation method of notoginseng-containing tablet for treating traumatic injury |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1840052A true CN1840052A (en) | 2006-10-04 |
| CN100387277C CN100387277C (en) | 2008-05-14 |
Family
ID=37029355
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNB2006100018231A Active CN100387277C (en) | 2006-01-23 | 2006-01-23 | Preparation method of notoginseng-containing tablet for treating traumatic injury |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN100387277C (en) |
Cited By (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101607040B (en) * | 2009-07-31 | 2011-09-14 | 孟庆华 | Drug for curing knife and gun injury and traumatic injury ulcerate as well as preparation method thereof |
| CN103565921A (en) * | 2013-11-04 | 2014-02-12 | 王立发 | Specific medicine for treating bedsore and promoting quick healing of wound |
| CN104173516A (en) * | 2014-08-25 | 2014-12-03 | 河南科技大学第一附属医院 | Combined medicine for treating traumatic injury and preparation method of combined medicine |
| CN105106521A (en) * | 2015-10-16 | 2015-12-02 | 韩守江 | Analgesic for traumatic injuries |
| CN105663867A (en) * | 2016-03-24 | 2016-06-15 | 周传杰 | Preparation method of traditional Chinese medicine for treating acute and chronic traumatic injury |
| CN113633708A (en) * | 2021-09-27 | 2021-11-12 | 重庆希尔安药业有限公司 | Preparation method of stable bruise treating qili composition tablet |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1537572A (en) * | 2003-04-15 | 2004-10-20 | 毛友昌 | Qili dispersing tablet for treating traumatic injuries, and its prepn. method |
| CN1537580A (en) * | 2003-04-15 | 2004-10-20 | 毛友昌 | Honghua Qili tablet contg. safflower carthamus, and its prepn. method |
-
2006
- 2006-01-23 CN CNB2006100018231A patent/CN100387277C/en active Active
Cited By (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101607040B (en) * | 2009-07-31 | 2011-09-14 | 孟庆华 | Drug for curing knife and gun injury and traumatic injury ulcerate as well as preparation method thereof |
| CN103565921A (en) * | 2013-11-04 | 2014-02-12 | 王立发 | Specific medicine for treating bedsore and promoting quick healing of wound |
| CN103565921B (en) * | 2013-11-04 | 2015-09-23 | 王立发 | A kind of medicine for the treatment of decubital ulcer and promotion wound healing |
| CN104173516A (en) * | 2014-08-25 | 2014-12-03 | 河南科技大学第一附属医院 | Combined medicine for treating traumatic injury and preparation method of combined medicine |
| CN104173516B (en) * | 2014-08-25 | 2016-03-16 | 河南科技大学第一附属医院 | A kind of combination medicine being used for the treatment of traumatic injury and preparation method thereof |
| CN105106521A (en) * | 2015-10-16 | 2015-12-02 | 韩守江 | Analgesic for traumatic injuries |
| CN105663867A (en) * | 2016-03-24 | 2016-06-15 | 周传杰 | Preparation method of traditional Chinese medicine for treating acute and chronic traumatic injury |
| CN113633708A (en) * | 2021-09-27 | 2021-11-12 | 重庆希尔安药业有限公司 | Preparation method of stable bruise treating qili composition tablet |
| CN113633708B (en) * | 2021-09-27 | 2022-02-11 | 重庆希尔安药业有限公司 | Preparation method of stable bruise treating qili composition tablet |
Also Published As
| Publication number | Publication date |
|---|---|
| CN100387277C (en) | 2008-05-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN1695694A (en) | Chinese traditional medicine for treating breast disease and preparing technique | |
| CN1840052A (en) | Preparation method of notoginseng-containing tablet for treating traumatic injury | |
| CN1250264C (en) | Capsule for curing hyperplasia of mammary glands and its preparation method | |
| CN1294015A (en) | Medicine for treating thyroid enlargement and thyroidism | |
| CN1429612A (en) | Thirty-six ingredients capsule for treating diabetes | |
| CN1973878A (en) | Medicine for treating children's stomachache and its prepn | |
| CN1823959A (en) | Heart vessel free flowing dispersion tablet and its preparation method | |
| CN1850167A (en) | Thirsty-relieving blood-sugar-reducing dropping pills and preparing method | |
| CN1709288A (en) | Medicinal composition, and its preparing method and use | |
| CN1739753A (en) | Psoriasis treating Chinese medicine prepn and its pren process | |
| CN1286501C (en) | Medicine composition for treating stomach disease, its preparation method and use | |
| CN1966032A (en) | Tablet with seven kinds of ingredients for treating stomach ache and preparation process thereof | |
| CN1775247A (en) | Fleece-flower root and rhizoma rehmanniae preparation and new preparing method | |
| CN100345534C (en) | Yinzhi huang capsule, its preparation method and use | |
| CN1186067C (en) | Medicine for curing acute injury of muscle and tendon and its preparation method | |
| CN1943691A (en) | A Chinese traditional medicinal composition for treatment of osteoporosis and its preparation method | |
| CN1768803A (en) | Medicine for treating hypertension and its preparing process | |
| CN1799603A (en) | Chinese traditional medicine composition for treating rheumatic or rheumatoid disease and preparation method thereof | |
| CN101032540A (en) | Medicine composition for curing arthritis and the preparing method and purpose thereof | |
| CN101032524A (en) | Application of martianus dermestoides in producing oxygen-deficient resisting medicine or healthy food and the preparing method | |
| CN1682930A (en) | Lemai dripping pill for treating cardiovascular diseases and its preparing method | |
| CN1843418A (en) | Traditional Chinese medicine extract for treating gastroenteritis and traditional Chinese medicine composition containing same | |
| CN1895405A (en) | Garden-Burnet-Sheng-Bai capsules and preparation thereof | |
| CN1220494C (en) | Notoginseng drop pills for calming nerve and curing insomnia etc. and preparation method | |
| CN101062260A (en) | Granule for complementing Yin and preventing anxiety |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| C56 | Change in the name or address of the patentee | ||
| CP02 | Change in the address of a patent holder |
Address after: Hilan road in Chongqing city of Hechuan Industrial Park Patentee after: Chongqing Hilan Pharmaceutical Co., Ltd. Address before: Floor 8, building B, hung Cheng Building, No. 33 Jianxin East Road, Jiangbei District, Chongqing Patentee before: Chongqing Hilan Pharmaceutical Co., Ltd. |